No insider purchase over the last 90 days. The latest, by COLL WAYNE M, was filed 01 Apr 2026.
This page follows insider dealings at Precision Optics Corporation, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 16 filings were filed, from 4 insiders.
Every open-market trade in the period is a purchase: 3 purchases worth €201k, from 3 insiders, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €131k, bought by Traut Joseph and made public on 1 April 2026. Among those who bought: 1 finance chief, 1 senior executive and 1 chief executive.
Within a 30-day window, 3 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 1 April 2026, 206 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4.
With 16 filings in twelve months, the company is quieter than the median of 28 filings across the 5,462 companies we follow on the same exchange. Since 2016, the database holds 16 purchases and 5 sales by insiders of the company. For the fiscal year to 30 June 2026, the annual 10-K puts revenue at 31.5 m USD and net income at -3.6 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2025 · cache
25 of 59 declarations
Precision Optics Corporation, Inc. (ticker: POCI) is a U.S.-based company listed on the Nasdaq Capital Market in the United States. It designs, develops, manufactures, and sells specialized optical and illumination systems and related components, with its business centered on the medical device and defense/aerospace markets. Founded in 1982 and publicly held since November 1990, the company is rooted in Massachusetts and has built a niche identity around advanced optical instruments, micro-optics, and highly miniaturized imaging solutions. For investors, POCI fits the profile of a small-cap, engineering-driven medical technology company whose results can be influenced by development-stage contracts, customer qualification timelines, and manufacturing ramp execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000867840/000168316825007305/poci_i10k-063025.htm?utm_source=openai))
Precision Optics’ operating model is organized around four core activities: systems manufacturing, engineering and product development, Ross Optical components and assemblies, and its micro-optics laboratory. This structure gives the company a vertically integrated value chain spanning concept design, prototyping, regulatory and engineering support, and eventual production. In medical applications, the company develops and manufactures endoscopes, endocouplers, micro-medical cameras, micro-lenses, and custom imaging devices, including single-use solutions and 3D endoscopy systems aimed at minimally invasive surgery and surgical robotics. In defense and aerospace, the same miniaturization expertise is adapted to mission-critical optical applications where size and weight constraints matter, including certain satellite communications-related uses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000867840/000168316825007305/poci_i10k-063025.htm?utm_source=openai))
The company’s history is a key part of the investment case. Precision Optics was incorporated in Massachusetts in December 1982 and has operated as a public company since 1990. A major strategic step came in 2019, when it acquired the operating assets of Ross Optical Industries in El Paso, Texas, broadening its presence in custom optical components and assemblies. More recently, management launched the Unity Imaging Platform in January 2025, a modular CMOS endoscopic platform intended to support customizable imaging systems. In 2026, the company also reported a strong increase in quarterly revenue, driven mainly by systems manufacturing growth, although the micro-optics lab has experienced order timing delays tied to defense customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000867840/000168316825007305/poci_i10k-063025.htm?utm_source=openai))
From a competitive standpoint, POCI is a specialist rather than a broad-based optics giant. Its differentiation lies in proprietary micro-optics know-how, custom design capability, integrated manufacturing, and the ability to serve demanding medical and defense clients with compact, high-performance optical systems. The company’s competitive edge is strongest where customers need highly customized, miniaturized imaging products that are difficult to source from mass-market suppliers. That said, investors should recognize the inherent risks of a niche business model: revenue can be lumpy, programs can shift between development and production at different speeds, and demand can vary materially by customer and end-market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000867840/000168316825007305/poci_i10k-063025.htm?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Jun 2026 | 31.5 m USD | -3.6 m USD | -0.43 USD | 10-K |
| Jun 2025 | 19.1 m USD | -5.8 m USD | -0.85 USD | 10-K |
| Jun 2024 | 19.1 m USD | -3.0 m USD | -0.49 USD | 10-K |
| Jun 2023 | 21.0 m USD | -144,613 USD | -0.03 USD | 10-K |
| Jun 2022 | 15.7 m USD | -928,416 USD | -0.18 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.